Dec 07, 2022 / 02:00PM GMT
Andrew Francis Galler - Morgan Stanley, Research Division - Equity Analyst
All right. Good afternoon, everyone. I'm Andrew Galler, one of the biotech analysts in Morgan Stanley. And I'm pleased to be joined today by Brett Monia, President and CEO of Ionis. Brett, thanks for joining us today.
Brett P. Monia - Ionis Pharmaceuticals, Inc. - Founder, CEO & Director
Thanks, Andrew. It's great to be here.
Andrew Francis Galler - Morgan Stanley, Research Division - Equity Analyst
And I just wanted to jump into a quick disclosure statement and then we can kick it off with Q&A. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. And with that, we can get into it.
Ionis Pharmaceuticals Inc at Nasdaq Investor Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot